This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: The Innovations of Matthew Jonathan Jones
Introduction
Matthew Jonathan Jones is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of novel co-crystal forms of platelet aggregation inhibitors. His work aims to address critical health issues related to arterial thrombotic complications.
Latest Patents
Matthew Jonathan Jones holds a patent for "Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor." This invention relates to novel co-crystal forms of a specific compound, where the co-former molecule can be selected from various acids, including glycolic acid and salicylic acid. The patent outlines processes for preparing these co-crystals, their pharmaceutical compositions, and their therapeutic applications in treating diseases such as coronary artery, cerebrovascular, or peripheral vascular disease.
Career Highlights
Matthew is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His role involves research and development focused on innovative solutions for complex medical challenges. His expertise in the pharmaceutical field has positioned him as a valuable asset to his team.
Collaborations
Matthew has collaborated with esteemed colleagues, including Anna Polyakova-Akkus and Stephen David Cosgrove. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.
Conclusion
Matthew Jonathan Jones exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborative efforts continue to pave the way for advancements in medical treatments.